Company Analysis Can-Fite BioPharma Ltd.
1. Summary
Advantages
- Price (2.14 $) is less than fair price (2.28 $)
- The stock's return over the last year (-1.61%) is higher than the sector average (-34.6%).
Disadvantages
- Dividends (0%) are below the sector average (1.23%).
- Current debt level 0.4004% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-122.28%) is lower than the sector average (ROE=-80.97%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Can-Fite BioPharma Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 6.7% | -0.1% | -1.4% |
| 90 days | -36.6% | -42% | 5.4% |
| 1 year | -1.6% | -34.6% | 31.2% |
CANF vs Sector: Can-Fite BioPharma Ltd. has outperformed the "Healthcare" sector by 32.99% over the past year.
CANF vs Market: Can-Fite BioPharma Ltd. has significantly underperformed the market by -32.86% over the past year.
Stable price: CANF is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CANF with weekly volatility of -0.031% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2.14 $) is lower than the fair price (2.28 $).
Price not significantly lower than the fair price: The current price (2.14 $) is slightly lower than the fair price by 6.5%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.99).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (47.35).
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.43) is lower than that of the sector as a whole (9.41).
P/BV vs Market: The company's P/BV (1.43) is lower than that of the market as a whole (22.57).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (12.04) is higher than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (12.04) is lower than that of the market as a whole (15.08).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.5758) is lower than that of the sector as a whole (17.46).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.5758) is lower than that of the market as a whole (22.75).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -4.07% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-4.07%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-14.25%).
5.4. ROE
ROE vs Sector: The company's ROE (-122.28%) is lower than that of the sector as a whole (-80.97%).
ROE vs Market: The company's ROE (-122.28%) is lower than that of the market as a whole (16.86%).
5.5. ROA
ROA vs Sector: The company's ROA (-76.42%) is lower than that of the sector as a whole (6.65%).
ROA vs Market: The company's ROA (-76.42%) is lower than that of the market as a whole (6.56%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.23%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
